TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06601998

Intervention type: OTHER
Intervention: Blood samples and Oropharyngeal swab
Description: Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

Intervention type: OTHER
Intervention: Blood samples and Oropharyngeal swab
Description: Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

Intervention type: OTHER
Intervention: Blood samples and Oropharyngeal swab
Description: Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

Intervention type: OTHER
Intervention: Blood samples and Oropharyngeal swab
Description: Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Description: * Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Description: * Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max

Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Description: * Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max
Study: NCT04970199

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser application on acupoints
Description: laser acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser application on acupoints
Description: laser acupuncture
Study: NCT06482463

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CSF sample
Description: an additional CSF sample of 1 ml is taken from the external ventriculostomy
Study: NCT05956470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and breathing program : Sudarshan Kriya Yoga (SKY)
Description: The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management education
Description: This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
Study: NCT04881695

Intervention type: OTHER
Intervention: Questionary patients
Description: The patients will answer 1 questionnaire consisting of 5 parts :~* General (demographic information)~* Desire for a child~* Hospital Anxiety and Depression scale~* Sexual life~* Additional questions regarding medical care

Intervention type: OTHER
Intervention: Questionary controls
Description: Witnesses will complete 1 survey containing 4 parts:~* General (demographic information)~* Desire to have a child~* Hospital Anxiety and Depression scale~* Sexual life
Study: NCT05171036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: * Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~* Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~* Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~* Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention.
Study: NCT04781608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: English: In It Together (IIT)
Description: Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
Study: NCT05856383

Intervention type: DRUG
Intervention: Inetetamab Combined With Pyrotinib and Vinorelbine
Description: Inetetamab Combined With Pyrotinib and Vinorelbine
Study: NCT04831827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR Reminder
Description: Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone call from research team
Description: Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR Portal message
Description: Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
Study: NCT05444062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational material and treatment recommendations for patients, general practitioners and pharmacists
Description: Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational material and treatment recommendations for patients, general practitioners and pharmacists
Description: Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
Study: NCT06482463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSF sample
Description: an additional CSF sample of 1 ml is taken from the external ventriculostomy
Study: NCT06171334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
Study: NCT05700500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shockwave therapy, barbotage and infiltration
Description: ultrasound guided interventions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shockwave therapy, barbotage and infiltration
Description: ultrasound guided interventions
Study: NCT06149585

Intervention type: OTHER
Intervention: Microbial Sampling
Description: Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences

Intervention type: OTHER
Intervention: Microbial Sampling
Description: Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
Study: NCT05226871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: Intramuscular (IM)

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: oral
Study: NCT05991336

Intervention type: GENETIC
Intervention: Gene therapy
Description: Autologous edited hematopoietic stem cell transplantation
Study: NCT05700500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shockwave therapy, barbotage and infiltration
Description: ultrasound guided interventions
Study: NCT06083870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oba01
Description: Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
Study: NCT04916600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NET
Description: NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NET
Description: NET is an investigational device that received CE-Mark in April 2009 as a Class IIa active medical device
Study: NCT05855369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation (TNS)
Description: Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Smell Training (ST)
Description: Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Smell Training (ST)
Description: Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Smell Training (PBO)
Description: Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
Study: NCT06390059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study: NCT05758831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfusion of treatment Rituximab
Description: Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion of treatment Ocrelizumab
Description: Perfusion of treatment (Ocrevus®)
Study: NCT05760157

Intervention type: OTHER
Intervention: Possible risk factors of heart failure
Description: Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.

Intervention type: OTHER
Intervention: Possible risk factors of heart failure
Description: Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
Study: NCT05056870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology
Description: CONTROL
Study: NCT05487404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: 3 oral doses of ADX-629 600 milligrams
Study: NCT06176599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenxiao Yuning decoction
Description: Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Study: NCT06157242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeruborbactam Oral Prodrug
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: Experimental
Study: NCT05694325

Intervention type: OTHER
Group type: OTHER
Intervention: peripheral blood and bone marrow withdrawal
Description: samples evaluation
Study: NCT05571527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma treatment
Description: Patients receive platelet-rich plasma via injection into the vaginal area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Hyaluronic Acid supplement
Description: Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
Study: NCT06484959

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions

Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions
Study: NCT05869942

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Light microscopic studies
Description: Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Light microscopic studies
Description: Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope. The pathological changes in vitiligenous skin will be detected

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemical studies
Description: Monoclonal HMGB1 and active caspase 3 antibodies

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemical studies
Description: Monoclonal HMGB1 and active caspase 3 antibodies
Study: NCT04871737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
Study: NCT05487404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 oral doses of placebo
Study: NCT05198037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihemispheric tDCS
Description: The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bihemispheric tDCS
Description: The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
Study: NCT06448338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyDiaMate
Description: MyDiaMate program